Genetic Repair of Familial Hypercholesterolemia

家族性高胆固醇血症的基因修复

基本信息

  • 批准号:
    10444520
  • 负责人:
  • 金额:
    $ 57.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-12-20 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

This is a competing renewal R01 application that seeks to develop new gene editing approaches to treat Familial Hypercholesterolemia (FH). FH is an autosomal dominant disease most often caused by loss-of-function mutations in the low density lipoprotein receptor (LDLR), the protein responsible for uptake of ApoB-containing lipoprotein particles (such as LDL) by the liver. Loss of both LDLR alleles in homozygous FH (HoFH) causes excessively high plasma cholesterol (~1000 mg/dl), xanthomas, atherosclerosis, and death in the first few decades of life if untreated. Currently, the only curative treatment for HoFH is a liver transplant, making this disease an important priority for gene therapy. Achieving permanent correction of HoFH through gene therapy will require modifying the patient’s own DNA, so that cells expressing LDLR will persist in the liver. In this application we will further expand on our previous work, by developing strategies to integrate a full length LDLR transgene into genomic safe harbor sites. The goal is to ensure that the therapy will be generalizable to HoFH patients, and not specific to a particular mutation or region of the protein. Secondly, we will use FH mouse models to test a new strategy for liver-directed gene therapy through selection expansion of gene-corrected hepatocytes. This approach capitalizes on the regenerative capacity of the liver, and uses endogenous essential gene as a selectable marker. Over time, inhibition of the essential gene can be used to selectively expand gene-targeted hepatocytes, ensuring that liver-wide correction can be achieved. We propose two specific Aims: 1) Determine if targeted integration at the Ldlr and Apoa1 loci can correct FH, and 2) Develop a novel system for selective expansion of gene- corrected hepatocytes. Completion of this work will produce a new gene therapy solutions for HoFH, as well as a universal system for genetic correction of other liver disorders through in vivo selection.
这是一个竞争性的更新R01申请,旨在开发新的基因编辑方法来治疗家族性高胆固醇血症(FH)。FH是一种常染色体显性疾病,最常由低密度脂蛋白受体(LDLR)的功能丧失突变引起,低密度脂蛋白受体负责由肝脏摄取含载脂蛋白b的脂蛋白颗粒(如LDL)。纯合子FH (HoFH)中两个LDLR等位基因的缺失会导致血浆胆固醇过高(~1000 mg/dl)、黄斑瘤、动脉粥样硬化,如果不治疗,在生命的最初几十年就会死亡。目前,治疗HoFH的唯一方法是肝移植,这使得这种疾病成为基因治疗的重要优先事项。通过基因治疗实现对HoFH的永久矫正需要修改患者自身的DNA,以使表达LDLR的细胞在肝脏中持续存在。在这个应用中,我们将进一步扩展我们之前的工作,通过开发策略将全长LDLR转基因整合到基因组安全港位点。我们的目标是确保这种疗法可以推广到HoFH患者,而不是针对特定的突变或蛋白质区域。其次,我们将使用FH小鼠模型,通过基因校正肝细胞的选择扩展来测试肝脏定向基因治疗的新策略。这种方法利用肝脏的再生能力,并使用内源性必需基因作为选择性标记。随着时间的推移,必需基因的抑制可以用来选择性地扩增基因靶向肝细胞,确保可以实现全肝范围的校正。我们提出了两个具体目标:1)确定Ldlr和Apoa1位点的靶向整合是否可以纠正FH, 2)开发一种新的系统来选择性扩增基因纠正的肝细胞。这项工作的完成将为HoFH提供一种新的基因治疗方案,以及通过体内选择对其他肝脏疾病进行基因校正的通用系统。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William Raymond Lagor其他文献

William Raymond Lagor的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William Raymond Lagor', 18)}}的其他基金

Genome Editing and Biological Effects Testing Section
基因组编辑及生物效应检测组
  • 批准号:
    10773478
  • 财政年份:
    2023
  • 资助金额:
    $ 57.35万
  • 项目类别:
Physiological Dissection of the Mevalonate Pathway
甲羟戊酸途径的生理解剖
  • 批准号:
    10359805
  • 财政年份:
    2020
  • 资助金额:
    $ 57.35万
  • 项目类别:
Physiological Dissection of the Mevalonate Pathway
甲羟戊酸途径的生理解剖
  • 批准号:
    10579186
  • 财政年份:
    2020
  • 资助金额:
    $ 57.35万
  • 项目类别:
Genetic Repair of Familial Hypercholesterolemia
家族性高胆固醇血症的基因修复
  • 批准号:
    10588157
  • 财政年份:
    2016
  • 资助金额:
    $ 57.35万
  • 项目类别:
Genetic Repair of Familial Hypercholesterolemia
家族性高胆固醇血症的基因修复
  • 批准号:
    10063884
  • 财政年份:
    2016
  • 资助金额:
    $ 57.35万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 57.35万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 57.35万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 57.35万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 57.35万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 57.35万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 57.35万
  • 项目类别:
    Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 57.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 57.35万
  • 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 57.35万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 57.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了